Analysis Tools
neoplasm
|
• at day 10 after subcutaneous (s.c) implantation of Lewis lung carcinoma (LCC) tumors, homozygotes show a ~3.6-fold reduction of Ki67+ nuclei within extracted tumor tissue relative to wild-type controls, indicating reduced cell proliferation
• LCC tumors extracted at day 10 from mutant mice exhibit massive necrotic cell death, as shown by immunoblotting of tumor lysates with an antibody against the 50 kDa necrotic cleavage fragment of PARP-1
|
|
• at day 10 after s.c implantation of LCC tumors, homozygotes display reduced microvascular density (MVD) within tumor tissue relative to wild-type controls, as shown by IHC using anti-CD31 anti-CD34 antibodies, suggesting impaired tumor-induced angiogenesis
• in contrast with day 10, only MVD but not cell proliferation and survival is decreased in the earliest palpable LLC tumors extracted 6 days after implantation
• at day 8 after s.c. implantation of B16-F10 melanoma tumors, homozygotes show a ~2.5-fold reduction in the number of CD31-positive vessels within tumor tissue relative to wild-type controls
|
|
• at day 10 after s.c implantation of LCC tumors, homozygotes show a ~13.3-fold increase of PSR staining within extracted tumor tissue relative to wild-type controls, suggesting increased deposition of extracellular collagen and fibrosis
• LCC tumors extracted at day 10 from mutant mice exhibit disrupted cellular/nuclear integrity, as shown by H&E staining
|
|
• after s.c. implantation of B16-F10 melanoma cells, homozygotes show a 3-fold reduction in B16-F10 tumor mass relative to wild-type controls at final day 14 of the experiment
|
|
• LLC tumors not only grow much slower within the earlier phase (up to ~10 days after s.c. implantation) but show a clear regression pattern between days 10 and 17, such that male homozygotes show a ~320-fold reduction of LLC tumor mass at day 17 relative to wild-type controls
• remarkably, all LLC tumors regress and all homozygotes remain tumor free when maintained up to 2 months after tumor implantation
• failure of LLC tumors to grow is gender independent
|
cardiovascular system
|
• at day 10 after s.c implantation of LCC tumors, homozygotes display reduced microvascular density (MVD) within tumor tissue relative to wild-type controls, as shown by IHC using anti-CD31 anti-CD34 antibodies, suggesting impaired tumor-induced angiogenesis
• in contrast with day 10, only MVD but not cell proliferation and survival is decreased in the earliest palpable LLC tumors extracted 6 days after implantation
• at day 8 after s.c. implantation of B16-F10 melanoma tumors, homozygotes show a ~2.5-fold reduction in the number of CD31-positive vessels within tumor tissue relative to wild-type controls
|
